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Desmin (DES) is a major muscle scaffolding protein that also functions to anchor
mitochondria. PathogenicDESmutations, however, have not previously been recognized
as a cause of multi-systemic mitochondrial disease. Here, we describe a 45-year-old
man who presented to The Children’s Hospital of Philadelphia Mitochondrial-Genetics
Diagnostic Clinic for evaluation of progressive cardiac, neuromuscular, gastrointestinal,
and mood disorders. Muscle biopsy at age 45 was remarkable for cytoplasmic
bodies, as well as ragged red fibers and SDH positive/COX negative fibers that were
suggestive of a mitochondrial myopathy. Muscle also showed significant reductions
in mitochondrial content (16% of control mean for citrate synthase activity) and
mitochondrial DNA (35% of control mean). His family history was significant for cardiac
conduction defects and myopathy in multiple maternal relatives. Multiple single gene and
panel-based sequencing studies were unrevealing. Whole exome sequencing identified
a known pathogenic p.S13F mutation in DES that had previously been associated
with desmin-related myopathy. Desmin-related myopathy is an autosomal dominant
disorder characterized by right ventricular hypertrophic cardiomyopathy, myopathy,
and arrhythmias. However, neuropathy, gastrointestinal dysfunction, and depletion of
both mitochondria and mitochondrial DNA have not previously been widely recognized
in this disorder. Recognition that mitochondrial dysfunction occurs in desmin-related
myopathy clarifies the basis for the multi-systemic manifestations, as are typical of
primary mitochondrial disorders. Understanding the mitochondrial pathophysiology of
desmin-related myopathy highlights the possibility of new therapies for this otherwise
untreatable and often fatal class of disease. We postulate that drug treatments aimed
at improving mitochondrial biogenesis or reducing oxidative stress may be effective
therapies to ameliorate the effects of desmin-related disease.
Keywords: desmin-related myopathy, DES, mitochondrial disease, whole exome sequencing, mitochondrial DNA
depletion
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Introduction
A 45-year-old Caucasian man presented to The Children’s
Hospital of Philadelphia Mitochondrial-Genetics Diagnostic
Clinic for evaluation of suspected mitochondrial disease based
on arrhythmia, cardiomyopathy, progressive lower extremity
myopathy, and peripheral neuropathy. His cardiac problems
presented as episodic dizziness and congenital heart block that
were noted in his late 20 s, with a pacemaker placed at 30
years of age. Over the next decade, he developed intermittent
atrial flutter, right hypertrophic cardiomyopathy, and congestive
heart failure. Myopathic symptoms began in his mid-late 30 s
with leg weakness that progressed following pneumonia at 38
years of age. By age 45, he was no longer able to run and had
significant difficulty ambulating. Electromyogram performed at
that time revealed a distal myopathy with myotonic discharges
and mild length-dependent neuropathy. A detailed review of
systems was significant for lifelong short stature, progressive
photophobia, hoarse voice, gastroesophageal reflux, swallowing
dysfunction, progressive truncal obesity, progressive bloating,
anger, and intermittent depression. Review of prior laboratory
screening studies were significant for an elevated GGT, elevated
indirect bilirubin, and elevated creatine kinase (315U/L). Prior
genetic testing only included DM1 and DM2 expansion analyses,
which were normal.
His family history was significant for multiple individuals with
cardiac and/or neuromuscular disease (Figure 1).
The proband’s physical examination at age 45 was significant
for short stature, distant heart sounds, abdominal obesity, small
hands, and cold and purplish-colored feet. He was unable to get
onto the exam table without assistance, but could lie back and sit
up withminimal assistance. He had profound thigh weakness and
was unable to lift either thigh even slightly without resistance. He
had normal 5/5 strength of the upper extremities, 4/5 strength
in the fingers, and 3–4/5 strength in the lower legs and feet with
significant calf muscle wasting. He had 1+ biceps and patellar
deep tendon reflexes, but ankle reflexes could not be elicited. He
had a slapping gait, was unable to perform toe or heel walking,
and had difficulty performing tandem gait. He was unable to
stoop at the knees and recover. He reported sharp and dull
sensation on his feet and legs.
Clinical follow-up at age 46 was notable for interval
development of progressive leg muscle weakness and tingling,
especially of the calves, progressive atrophy of arm and leg
muscles, increased leg swelling, and a constant cold sensation
of his legs. Physical examination revealed cervical kyphosis and
2+ pitting edema of the legs with swollen ankles obscuring all
landmarks. He no longer could sit up withminimal assistance but
instead needed to roll onto his side to get from a supine to a sitting
position. Upper extremity strength was stable. He reported an
inability to feel the floor with his feet and now had only minimal
control of foot and ankle movements. Patellar and ankle DTRs
could not be elicited.
Metabolic laboratory studies performed at age 45 were
normal, including a comprehensive chemistry panel, complete
blood count, lipoprotein profile, thyroid function screen, plasma
and urine amino acid quantitative analyses, pyruvate, lactate,
FIGURE 1 | Family history. II-2 had pacemaker placement at 38 years of age
and sudden cardiac death at age 62. III-3 had dizziness and syncope onset at
age 30, cardiac conduction block requiring pacemaker placement at age 30,
extremity weakness and calf muscle wasting onset in the mid-50 s; choking
episodes beginning in the 50 s, and hand numbness and tingling onset in the
late 20 s that largely resolved following carpal tunnel surgery. In addition, she
developed obesity, photophobia, a progressively enlarging palatal cyst
protruding to her right nostril resulting in limited sense of smell at age 30,
difficulty hearing with background noise in her mid-50 s; and irritable bowel
syndrome with alternating constipation and diarrhea in her early 50 s. III-2 has
intellectual disability and autism. I-1 died at age 39 from presumed sudden
cardiac death, had a history of “dropsy” with recurrent syncope, edema, and
dizzy spells. I-2 died at age 92 years from cancer and required pacemaker
placement in her 70 s. IV-3 had tachycardia requiring ablation at 10 years of
age.
ammonia, carnitine analysis, acylcarnitine profile, urinalysis, and
urine organic acid analysis, with the only exception being amildly
elevated creatine kinase activity (258U/L, normal 55–170U/L).
Left quadriceps muscle biopsy was performed at age 45, which
revealed generalized muscle fiber atrophy with fatty-fibrous
tissue infiltration. Ragged red fibers and SDH positive/COX
negative fibers consistent with a mitochondrial myopathy
were identified (Figure 2). No ultrastructural mitochondrial
morphologic abnormalities were evident by electron microscopy
although two cytoplasmic bodies were present.
Muscle mitochondrial DNA content by quantitative PCR
analysis revealed mitochondrial DNA depletion, at 35% of
the mean value of age- and tissue-matched controls. Per
BaylorMedical Genetics Clinical Diagnostic Laboratory standard
techniques, mitochondrial and nuclear DNA contents are
determined by real-time quantitative PCR using specific primers
for the mitochondrial tRNALeu(UUR) gene and the nuclear ß-
2-microglobulin (ß2M) gene (Bai et al., 2004; Bai and Wong,
2005; Dimmock et al., 2008, 2010; Wong et al., 2008; Venegas
et al., 2011). The mitochondrial DNA copy number is calculated
from the difference in threshold cycle numbers of mitochondrial
DNA and nuclear DNA. Control samples were obtained from
over 300 individuals suspected of having mitochondrial disease
but mutations in genes known to cause mitochondrial DNA
depletion were not identified.
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FIGURE 2 | Proband’s skeletal muscle cryostat sections.Muscle
sections stained with (A) H&E or (B)modified Gomori trichrome stain
demonstrate marked variability in fiber size, with fiber atrophy and fatty
infiltration. Ragged red fibers are marked by arrows in both panels. (C)
SDH/COX staining demonstrated several fibers (arrow) with SDH activity (blue)
that lack COX activity (brown). Original magnifications: (A), 200X; (B,C), 400X.
Muscle mitochondrial DNA sequencing by next-generation
sequencing did not detect large deletions or known deleterious
point mutations.
Muscle mitochondrial respiratory chain enzyme activity
analyses revealed significant deficiency of overall mitochondrial
content as evidenced by citrate synthase activity reduced
to 16% of the control mean; relative deficiency of several
electron transport chain enzyme activities was also present that
largely normalized (complex II+III) or improved to >30%
of control (complex II, complex IV) when corrected for the
low citrate synthase activity (Table 1). This reduction after
correction for citrate synthase may suggest that, in addition to
reduced mitochondrial mass, the energetic efficiency may be
compromised. Per Baylor Medical Genetics Clinical Diagnostic
Laboratory standard technique, the electron transport chain
enzymes were assayed at 30◦C using a temperature-controlled
spectrophotometer. The activities of complex I, complex II,
complex I+III, complex II+III, and complex IV were each
measured in duplicate using different electron acceptors/donors.
The increase or decrease of cytochrome c at 550 nm was
measured for complex I+III, II+III, or complex IV. The
activity of complex I was measured by following the oxidation
of NADH at 340 nm. For complex II, the reduction of 2,6-
dichloraindophenol (DCIP) at 600 nm was measured. Enzyme
activities were normalized against citrate synthase activity (Ye
and Hoppel, 2013; Vigelsø et al., 2014) as citrate synthase was
greater than one standard deviation above or below control
mean (Trounce et al., 1996; Walker et al., 1996; Bernier et al.,
2002; Gellerich et al., 2004; Enns et al., 2005; Kirby et al.,
2007). The 95% confidence interval is used as control, with
several hundred individuals included in each control range.
Additionally, a concurrent mouse muscle wild type control is
analyzed with each enzymologic assay for quality control.
Genetic testing was performed in sequential fashion. At age 45,
blood-based mitochondrial DNA sequencing by next-generation
sequencing analysis and frataxin gene expansion analysis were
normal. Following muscle biopsy studies, LMNA sequencing was
recommended and was normal, as was sequencing, deletion, and
duplication analysis of 101 nuclear genes known to be associated
with mitochondrial disease. Whole exome sequencing (WES) on
a clinical diagnostic basis at Baylor Medical Genetics Laboratory
was then recommended, although no parental samples were
available for analysis. WES identified a known mutation in
the DES gene, namely c.38C>T;p.S13F, that was previously
associated with desmin-related myopathy. Specifically, the
p.S13F mutation had previously been reported as a disease-
causing founder mutation in Dutch patients reported to have
skeletal muscle weakness and cardiac involvement (Bergman
et al., 2007; van Spaendonck-Zwarts et al., 2012). Targeted p.S13F
mutation analysis in his symptomatic, maternal half-sister was
positive and negative in his niece with a history of tachycardia
requiring ablation at 10 years of age. The family is considering
targeted mutation analysis in proband’s full brother and children.
Background
Desmin-related myopathy caused by missense mutations in
DES has been recognized to be a fully penetrant, autosomal
dominant condition with variable manifestations that largely
include myopathy, cardiomyopathy, and arrhythmias (Goldfarb
et al., 1998; Dalakas et al., 2000; Bergman et al., 2007; van
Spaendonck-Zwarts et al., 2012). Desmin expression is highest in
heart, followed by muscle, and gastrointestinal tract1. However,
there is also expression known in the peripheral nerve and
reproductive organs including cervix, prostate, and uterus. The
p.S13F mutation identified in the family described here is a
previously identified, well-characterized pathogenic alteration
and was first recognized as a disease-causing founder mutation in
Dutch patients with varying degrees of skeletal muscle weakness
and cardiac involvement (Dalakas et al., 2000). Prior phenotypic
analysis of individuals carrying the p.S13F mutation in DES
found that all individuals had cardiac conduction disease and/or
cardiomyopathy while neuromuscular features were not present
in everyone (van Spaendonck-Zwarts et al., 2012). Both the
proband and his maternal half-sister in the present family had
cardiac and neuromuscular involvement, both of which were
more severe and progressed at an earlier age in the proband,
1GeneHub-GEPIS. Available online at: http://research-public.gene.com/cgi-
bin/genentech/genehub-gepis/web_search-result.pl?id=GENE2507&CHR=CHR2
&CHR_END=219999704&CHR_START=219991342&DESCT=desmin&END=4
68412689&GENE_NAME=DES&ID=GENE2507&SPECIES=HUMAN&START=
468404327&STRAND=1&intype=1&xrefid=DES&species=human
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TABLE 1 | Muscle mitochondrial respiratory chain enzyme activity analyses.
Electron transport chain
activities
ETC
complexes
Percent of mean
(before correction for
decreased citrate
synthase) (%)
Percent of mean (after
correction for
decreased citrate
synthase) (%)
Patient activity
(nmol/min/mg protein)
Control ± standard
deviation (nmol/min/mg
protein)
NADH:cytochrome c
reductase (rotenone
sensitive)
Complex I+III 0 0 0 9.1 ± 2.5
Succinate dehydrogenase Complex II 6 40 0.51 8.11 ± 2.44
Succinate:cytochrome c
reductase
Complex II+III 18 115 0.87 4.9 ± 1.1
Cytochrome c oxidase Complex IV 6 39 1.8 29.2 ± 9.1
Citrate synthase 16 100 44 280 ± 95
as well as gastrointestinal dysfunction in both and progressive
neuropathy and mood disorder in the proband. Our proband
also had two cytoplasmic bodies identified on his muscle biopsy
histology, which are not specific but can be seen in desmin-
related myopathies. While the proband’s niece with a history
of tachycardia in childhood did not harbor the familial DES
mutation, there are many recognized non-inherited causes of
arrhythmia that could have been the source in this individual.
Discussion
While the cardiac and neuromuscular phenotype of desmin-
related myopathy is well characterized, there is scarce reported
literature on desmin-related myopathies being associated with
mitochondrial dysfunction or disease. Desmin (DES) is a key
scaffolding protein found in muscles that is known to function
as a mitochondrial anchor (Stromer and Bendayan, 1988).
Prior studies in desmin-null mice revealed subsarcolemmal
accumulations of mitochondria in muscle and overall increased
numbers of mitochondria, as well as impaired mitochondrial
respiratory capacity (Milner et al., 2000). One previous
case report in a man with a frameshift DES mutation
(c.5141_5143insA; p.K239fsX242) revealed clustering of muscle
mitochondria, normal respiratory chain enzymology in skeletal
muscle homogenates, and decreased maximal rates of respiration
and complex I in isolated saponin-permeabilized skeletal
muscle fibers (Schroder et al., 2003). However, there was
no report of decreased mitochondrial mass or mitochondrial
DNA content either in that case or more generally in
desmin-related myopathy. Additionally, two siblings with
progressive muscle fatigue and weakness were found to be
compound heterozygous for mutations in DES with carrier
status confirmed in both asymptomatic parents. Muscle biopsy
in one of these siblings revealed myopathic features, 5%
COX deficient fibers on immunohistochemical analysis, and
absent desmin staining. No mitochondrial DNA sequencing,
mitochondrial DNA content analysis, nor enzymatic activity
assays of mitochondrial respiratory chain function was reported.
Electron microscopy showed no structural abnormalities in the
mitochondria although there was variability noted in their size
and distribution (Henderson et al., 2013).
Additionally, while only muscle mitochondrial DNA content
was assessed in this proband, it is not unreasonable to postulate
that his multisystemic involvement can be due to muscle and/or
peripheral nerve involvement. Indeed, neurogenic disease and/or
polyneuropathy was reported on electromyogram analysis of at
least three other individuals with DES mutations, including one
confirmed to have the p.S13F mutation (Bergman et al., 2007).
Concluding Remarks
We report here a case of progressive cardiac and neuromuscular
disease that was clinically suspected as a mitochondrial disorder
based on his progressive, multi-systemic involvement including
neurologic, gastrointestinal, and mood manifestations. Muscle
biopsy in this case revealed ragged red fibers and SDH
positive/COX negative fibers, findings consistent with classical
primary mitochondrial disease, as well as pronounced depletion
of mitochondrial DNA content and reduced mitochondrial mass,
and complex I deficiency. Numerous single-gene and panel-
based molecular analyses were unrevealing. Clinically-based
whole exome sequencing revealed the underlying etiology in
the proband and his similarly affected sister to be a previously
reported pathogenicmutation in theDES gene. This case expands
the phenotype of desmin-related myopathy to include clinical
features in the nervous and gastroenterologic systems, as are
typical of mitochondrial disease. Recognizing that significant
mitochondrial depletion occurs in desmin-related myopathy is
especially important to enable development of new therapeutic
avenues for this progressive and often fatal disease, such as
potentially through stimulation of mitochondrial biogenesis
or reduction of oxidative stress that commonly occurs in
mitochondrial disorders (Parikh et al., 2009). Finally, these data
are suggestive that there may exist other neuromuscular diseases
caused by mutations in structural proteins that interact directly
with mitochondria.
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